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Atherosclerosis is a multifactorial chronic inﬂammatory disease characterized by the presence of T-cells,
macrophages, and dendritic cells in the arterial intima. Classical risk factors lead to over-expression of
stress proteins, especially heat shock protein 60 (HSP60). HSP60 on the surface of arterial endothelial
cells (ECs) then becomes a target for pre-existing adaptive anti-HSP60 immunity resulting in inﬁltration
of the intima by mononuclear cells. In the present study, T-cells derived from early, clinically still
inapparent human atherosclerotic lesions were analyzed phenotypically and for their reactivity against
HSP60 and HSP60-derived peptides. HSP60 was detected in ECs and CD40- and HLA Class II-positive cells
within the intima. Effector memory CD4þ T-cells producing high amounts of interferon-g and low levels
of interleukin-4 were the dominant subpopulation. T-cells derived from late lesions displayed a more
restricted T-cell receptor repertoire to HSP60-derived peptides than those isolated from early lesions.
Increased levels of soluble HSP60 and circulating anti-human HSP60 autoantibodies were found in
donors with late but not early lesions. This is the ﬁrst functional study of T-cells derived from early
human atherosclerotic lesions that supports the previously proposed concept that HSP60-reactive T-cells
initiate atherosclerosis by recognition of atherogenic HSP60 epitopes.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Atherosclerosis is a multifactorial, inﬂammatory disease char-
acterized by the presence of T-cells, macrophages, and dendritic
cells (DCs) in the arterial intima in response to injury caused by
classical atherosclerosis risk factors. Adhesion molecules and
chemotactic factors mediate migration of cells of the immune
system into the arterial wall. Leukocyte adhesion and rolling
depend on P- and E-selectins and intercellular and vascular cell
adhesion molecules 1 (ICAM-1 and VCAM-1) [1], while monocyte
migration is mediated by monocyte chemotactic protein (MCP-1)
and its receptor CCR2 [2,3].
Under physiological conditions, the stress protein heat shock
protein 60 (HSP60) functions as a chaperone known to assist
protein folding and intracellular transport. HSP60 is typically
expressed in the mitochondria and is highly conserved with 97%fax: þ43 512 9003 73960.
.
-NC-ND license.homology between bacterial species and more than 50% homology
between microbial and human molecules [4]. HSP60 is a strongly
immunogenic microbial antigen able to induce protective humoral
and cellular immune responses. Exposed to classical atherosclerotic
risk factors, ECs simultaneously express HSP60 and adhesion
molecules on their surface [5,6]. HSP60 surface expressions have
been shown in stressed human umbilical venous endothelial cells
(HUVECs) and aortic endothelial cells (ECs) [7e9] and also in
bacterially infected HUVECs [10,11]. HSP60-expressing ECs can then
become target cells for pre-existing cellular and humoral immunity
against this ubiquitous protein leading to the formation of
inﬂammatory lesions in the intima.
In humans, T-cells isolated from surgically removed advanced
(late) atherosclerotic lesions (LL ¼ plaques) which recognize HSP60
have a restricted T-cell receptor (TCR)a/b repertoire and predomi-
nantly produce Th1 cytokines [12,13]. It has also been shown that
increased levels of anti-HSP60 autoantibodies correlate with the
severity of LL [14]. Furthermore, studies performed in animals
following immunization with HSP60 have shown excessive plaque
formation under normo and hypercholesterolemic conditions
[15e17].
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against HSP60 in the development and progression of atheroscle-
rosis. However, the role of HSP60 in the initiation of atherosclerosis
is still unclear. To our knowledge, the present study is the ﬁrst to
investigate phenotypic and functional characteristic of T-cells iso-
lated from early, clinically still inapparent human atherosclerotic
lesions (EL) and to compare thesewith data on LL byevaluating their
reactivity to humanHSP60 (hHSP60) and hHSP60-derived peptides.
2. Material and methods
The study was approved by the Ethics Committee of the Inns-
bruck Medical University (#UN2670).
2.1. Atherosclerotic lesions
2.1.1. Early atherosclerotic lesions (EL)
Iliac arteries with clinically and macroscopically inapparent
early atherosclerotic lesions at the known predilections sites [18] at
arterial branching points as well as blood samples from 7 healthy
transplant organ donors (5 male, 2 female, age: 54 5.4 years) who
died due to cerebrovascular incidents (brain death) were obtained.
All clinical data are presented in Table 1. In three cases (EL 2, 4, and
5), pathohistological data were not available. In these instances,
macroscopically healthy, very small arterial tissue specimens were
taken from the known predilection sites at the branching point of
the iliac artery and immediately processed in toto for cell cultures.
The higher serum values of C-reactive protein (CRP) in EL donors as
compared to LL patients was due to the fact that these brain death
individuals were kept under intensive care conditions known to be
associated with an “inﬂammatory storm” [19]. Pathological classi-
ﬁcation of atherosclerotic lesions (score IeVI, see Table 1) was
performed according to the criteria recommended by the American
Heart Association [20]. Austria is part of Eurotransplant and
complete laboratory values are often not available from donors the
organs of whom are transported to the local transplantation unit.
2.1.2. Late atherosclerotic lesions (LL)
Internal carotid arteries with advanced atherosclerotic lesions
were obtained from 8 patients undergoing surgery either for
symptomatic or high-grade asymptomatic stenosis with written
informed consent (6 male, 2 female, age: 74.2 3.1 years). Formore
detailed clinical information see Table 1. Informed consent was
obtained from all donors of LL.
2.2. Peripheral blood mononuclear cells (PBMCs) and plasma
PBMCs were obtained by density gradient centrifugation (GE
Healthcare Bio-Sciences AB; Sweden) from freshly drawn venous
blood. After washing, PBMC were resuspended in RPMI 1640
(Lonza, Belgium) supplemented with 1% penicillin/streptomycin,
1% glutamine, and 10% fetal calf serum (FCS; Serum Supreme,
Lonza, Belgium). Plasma samples were obtained from all 7 donors
with EL and 8 patients with LL and two healthy age- and sex-
matched control groups, one young control group (Control Y; age:
33 4 years; n ¼ 26) and one elderly control group (Control E; age:
74  4 years; n ¼ 14). PBMCs were kept at 80 C until used for
expansion. Plasma samples were stored at 20 C until use.
Informed consent was obtained from all healthy controls.
2.3. Immunohistochemistry
The presence of CD1a, CD3, CD4, CD8, CD40, CD68, tryptasemast
cells, CD106 (VCAM-1), and CD62E (E-selectin) molecules were
analyzed by immunohistochemistry in formalin-ﬁxed, parafﬁn-embedded arterial specimens from 4 EL and 8 LL donors (see
Supplementary Table 1). Brieﬂy, eight-mm-thick tissue slides were
treatedwith xylene (3 for 3min),100% ethanol (2 for 2min), 96%
ethanol (2 for 3 min), 70% ethanol (1 for 3 min), TBS (pH ¼ 7.2)
(1 for 3 min), and ﬁnally washed in water. Antigen retrieval was
achieved either with 1 epitope retrieval solution, pH ¼ 9, (Eubio,
Austria) or 0.5 M EDTA for 10 min at 750 W in a microwave oven.
Slides were cooled, rinsed with TBS, and blocked either for 6 min
with ultra-V block solution (Thermo Scientiﬁc, USA) or overnight
with blocking buffer (5% in TBS), (Roche Diagnostics, Germany)
containing 10% FCS. Following the blocking step, slideswerewashed
(3 for 5 min) with TBS at room temperature (RT). Antibodies and
corresponding controls (Supplementary Figure 1)were added to the
tissue sections as shown in Supplementary Table 1 and incubated for
1 h at RT. Following 3 further washing steps and addition of primary
antibody enhancer (Thermo Scientiﬁc, USA) the sections were ﬁrst
incubated for 10 min at RT with the primary antibody enhancer and
then treatedwith AP-polymer (Thermo Scientiﬁc, USA) for 15min at
RT. For visualization, either fast red (SigmaeAldrich, USA) or 3,30
diaminobenzidine (DAB) (SigmaeAldrich, USA) was used when AP-
anti-mouse or HRP-anti-mouse antibody was applied, respectively.
Stainingwasmonitoredmicroscopically and color developmentwas
stopped with water. Nuclear staining was performed by incubation
of the slides with Mayer’s hemalum solution (1:10) for 10 min.
2.4. Immunoﬂuorescence
To identify HSP60-expressing cells in atherosclerotic lesions,
triple immunoﬂuorescence staining was performed. Parafﬁn
embedded tissueswere processed as indicated before. Following the
blocking step, the sectionswere treatedwith eithermonoclonal anti-
human antibodies for ECs (vWF), CD40, CD106 or anti-HLA-DR, DP,
DQ and corresponding controls (Supplementary Figure 1) incubated
for 1 h at RT. Slides were washed (3 for 3 min) in TBS to remove
excess antibody. For visualization, goatAlexa488 labeledanti-mouse
IgG (Invitrogen, USA) was applied to the sections and incubated for
1 h in the dark at RT. HSP60 expression, in combination with the
markers indicated above, was determined ﬁrst by incubation with
polyclonal rabbit anti-human HSP60 IgG (Santa Cruz Biotechnology,
USA) for 1hand thenby incubationwithgoatAlexa568-labeledanti-
rabbit IgG (Invitrogen, USA) for 1 h at RT in the dark. Nuclear staining
wasachievedby incubationwithHoechst stain (1:40,000) for10min.
Microscopic analyses and documentation were carried out at room
temperature with a Nikon Eclipse E800 microscope connected to
Digital Sight DS-5M with a DS-L1 control unit (Nikon, Japan).
3. Generation of T-cell lines from early atherosclerotic lesions
EL and LL from 7 to 8 donors respectively, were cut into small
pieces and cultured in RPMI 1640 medium (Lonza, Belgium) sup-
plemented with 1% penicillin/streptomycin, 1% glutamine (Lonza,
Belgium), 7% human serum (Type AB; Lonza, Belgium) and
recombinant human interleukin (rhIL)-2 (20 U/mL) for 7 days in
a petri dish (Sarstedt, USA). T-cells migrating out of the tissue
fragments were harvested and cell suspensions were ﬁltered
through a cell strainer (100 mm; Becton Dickinson, USA). The T-cell
suspension was then transferred to a 24-well plate (Sarstedt, USA).
These T-cells were then expanded by stimulation with 1 mg/mL
each of anti-human anti-CD3/anti-CD28 antibodies (eBioscience,
Austria) in the presence of autologous irradiated PBMCs and rhIL-2
(10 U/mL) for 7 days. After expansion, intralesional hHSP60-speciﬁc
T-cell blasts were stimulated with recombinant human HSP60
(rhHSP60) protein (10 mg/mL) together with autologous feeder cells
in the presence of rhIL-2 (10 U/mL) once a week for two weeks. Cell
culture medium and rhIL-2 (10 U/mL) were replaced every third
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typic and functional studies.
3.1. Phenotypic characterization
Phenotypic characterization of intralesional hHSP60-speciﬁc T-
cells from 7 EL and 8 LL donors was performed using monoclonal
antibodies speciﬁc for CD3, CD4, CD8, CD45RA, CD45RO, CD28, and
CD25 (all purchased from BD Pharmingen, USA) labeled with
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin
chlorophyll protein (PerCP), or allophycocyanin (APC) for 30 min at
4 C. Subsequently, cells were washed twice with FACS buffer (0.5%
BSA in PBS) and measured by four-color ﬂow cytometry. Mouse IgG
isotype controls and unstained cells were used to deﬁne the level of
non-speciﬁc background signal (Supplementary Figure 2). All
analyses were performed using a FACSCalibur ﬂow cytometer
utilizing CELLQuest software (BD Pharmingen, USA).
3.2. Intracellular cytokine staining
Interferon (IFN)g, IL-4, IL-10 (BD Pharmingen, USA), IL-17
(Peprotech, USA), and transforming growth factor (TGF)b (R&D
systems, USA) productionwas determined in intralesional hHSP60-
speciﬁc T-cells from 7 EL and 8 LL donors by intracellular staining.Table 1
Demographic and clinical characteristics of patients with early and late lesions (plaques)
Demographic and clinical characteristics
EL/LL Age Sex BMI Smoker DM Infections Hypercholesterolemia CRP H
EL1 65 F 36 ND No No No 1.45 Y
EL2a 46 M 24 ND No Urinary
tract
infection
Yes 2.67 Y
EL3 48 M 28 Yes No No Yes 9.8 Y
EL4a,b 55 F 19 No No No Yes 0.5 N
EL5a 70 M 26 No No No ND 31.9 N
EL6 65 M 25 ND No No ND 1.55 Y
EL7 29 M 25 No No No No 10.6 N
LL1 70 M 29.2 No Yes No Yes 0.07 Y
LL2 77 M 21 No No Candidiasis Yes 0.06 Y
LL3 82 F 18.2 Nob No No No 0.06 Y
LL4 72 F 25.5 No No No Yes 0.2 Y
LL5 85 M 22.6 No No No Yes 0.7 Y
LL6 76 M 20.6 No No No No 0.07 Y
LL7 56 M 25.5 Yes No No Yesc 0.4 N
LL8 75 M 23.5 No No No Yes 0.15 Y
EL ¼ early lesion, LL ¼ late lesion (plaques), F ¼ female, M ¼ male, BMI ¼ body mass
CVD ¼ cardiovascular disease, CHD ¼ coronary heart disease, MI ¼ myocardial infarction
ACM ¼ arteria cerebri media infarction, NSTEMI ¼ non-ST-elevation myocardial infarcti
a No tissue for immunohistochemistry.
b Exsmoker for 10 years.
c Normal cholesterol levels but increased triglyceride levels.T-cells were stimulated with 30 ng/mL phorbol myristate acetate
(PMA) and 5 mg/mL ionomycin/mL in the presence of 10 mg of
brefeldin A/mL for 4 h at 37 C (SigmaeAldrich, USA). After washing
with PBS, stimulated T-cells were resuspended in FACS buffer and
incubatedwithmonoclonal antibodies for CD4-FITC and CD8-PerCP
for 30 min at 4 C. Following two washing steps, cells were resus-
pended in Cytoﬁx-Cytoperm (BD Pharmingen, USA) according to
the speciﬁcations of the manufacturer. Monoclonal antibodies
against IFNg, IL-4, IL-10, IL-17, and TGFb were added to the stimu-
lated cells resuspended in perm-wash buffer (BD Pharmingen, USA)
for 30 min at 4 C. Intracellular cytokine production was measured
by ﬂow cytometry. Mouse IgG isotype controls and unstained cells
were used to deﬁne the level of non-speciﬁc background signal
(Supplementary Figure 2). All analyses were performed in a FACS-
Calibur ﬂow cytometer utilizing CELLQuest software.3.3. Intralesional T-cell reactivity to hHSP60 protein and hHSP60-
derived peptide pools
To span the 573-long amino acid sequence of the hHSP60
protein, 113 15-mer synthetic peptides overlapping 10 amino acids
were produced (Peptides and Elephants, Germany). Twelve peptide
pools containing equal amounts of 10 overlapping peptides were
used in each pool (Supplementary Table 2). T-cells (1  104) were.
ypertension History
of CVD
Therapy Lesion
score
IeIV
es PAE Antibiotics, anticoagulation, antidiabetic,
antihemorrhagic, catecholamine,
cardiovascular medication, protone pump
inhibitor, thyroidal, ureostatic
II
es No Antibiotics, anticoagulation, antidiabetic,
antidiuretic, cardiovascular medication,
protone pump inhibitor, steroid, secretolytic
ND
es No Antibiotics, antidiabetic, cardiovascular
medication
II
o No Catecholamine ND
o No Antidiuretic ND
es No Analgesic, antibiotic, anticoagulation,
cardiovascular medication, protone
pump inhibitor
II
o No Antibiotic, catecholamines II
es No Anticoagulation, cardiovascular medication,
protone pump inhibitor, respiratory tract,
steroid
V
es CHD, MI,
PAOD
Anticoagulation, cardiovascular medication,
protone pump inhibitor
V
es No Anticoagulation, cardiovascular medication,
neuroleptic medication
V
es No Anticoagulation, cardiovascular medication V
es CHD, PAOD,
ACM
infarction
Anticoagulation, cardiovascular medication V
es ACM
infarction
Anticoagulation, protone pump inhibitor,
ureostatic
V
o CHD,
NSTEMI,
stroke
Anticoagulation, antidepressivum/
antipsychotic/antiepileptic, cardiovascular
medication, vitamin
V
es CHD, TIA,
ACM
infarction
Anticoagulation, cardiovascular medication V
index, ND ¼ not determined, DM ¼ diabetes mellitus, CRP ¼ C-reactive protein,
, PAE ¼ pulmonary artery embolism, PAOD ¼ peripheral arterial occlusive disease,
on, TIA ¼ transient ischemic attack.
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stimulated with either 10 mg/mL rhHSP60 or peptide pools inwhich
each peptide component was present at 10 mg/mL, in a 96-well
plate (Sarstedt, USA). Anti-human anti-CD3/anti-CD28 antibodies
(1 mg/mL each) and PHA (5 mg/mL) (SigmaeAldrich, USA) were used
as positive controls. After 3 days of incubation, cells were pulsed for
the last 10 hwith 1 mCi of 3H-thymidine (ICN Biomedicals Inc., USA).
3H-thymidine incorporation was assessed by scintillation counting.
All assays were carried out in triplicates. The response to a given
peptide pool was considered positive when the stimulation index
was higher than two.3.4. hHSP60-speciﬁc epitope recognition by intralesional T-cells
To identify HSP60 peptide-speciﬁc responses, 1  104 intrale-
sional atherosclerotic T-cells from 7 EL and 8 LL donors were co-
cultured with 5  104 autologous irradiated PBMCs andFig. 1. Immunohistological analysis of human atherosclerotic lesions. HSP60 expression (re
ﬂow conditions (vWFþ, green, 200, scale bar 200 mm) with simultaneous expression of ad
CD62E (40, scale bar 100 mm). Mononuclear cells in the intima expressed (E) CD40þ (
macrophages (CD68þ, brown), (I) mast-cells (tryptaseþ), (J) DCs (CD1aþ), (K) CD4þ T-cells, an
T-cells, and (P) CD68þ were identiﬁed in advanced atherosclerotic lesions. Images were acq
100 mm). All immunohistological stainings and analysis of these were performed at least th
demonstrated here.stimulated with 10 individual peptides (10 mg/mL) contained in the
corresponding positive responder pool. All 7 EL and 8 LL were used
individually in these experiments. As indicated before, monoclonal
anti-human anti-CD3/anti-CD28 antibodies and PHA were used as
positive controls. A non-related peptide (pepC, AAAAEEEEE, 10 mg/
mL; Bachem, Germany) was used as a negative peptide control.
After 3 days of incubation, cells were pulsed with 1 mCi of 3H-
thymidine. 3H-thymidine incorporation was assessed by scintilla-
tion counting. All assays were carried out in triplicates. The
response to a given peptide was considered positive when the
stimulation index was higher than two.3.5. Enzyme-linked immunosorbent assay (ELISA)
3.5.1. Soluble HSP60 (sHSP60) protein
The concentration of sHSP60 was assessed in plasma samples
from persons with 7 early and 8 late lesions and healthy (young:d) was determined in (A) ECs at arterial bifurcation areas stressed by turbulent blood
hesion molecules as (B) VCAM-1 (CD106, green, scale bar 200 mm), (C) CD106, and (D)
green) and (F) HLA-DRþ (green, 200, scale bar 200 mm). Subsets of (G) CD3þ, (H)
d (L) CD8þ T-cells were identiﬁed inﬁltrating the intima. (M) CD3þ, (N) CD4þ, (O) CD8þ
uired using a Nikon Eclipse E800 microscope. Original magniﬁcation 600 (scale bar
ree times. A representative immunohistological analysis from 4 EL and 8 LL donors are
G. Almanzar et al. / Journal of Autoimmunity 39 (2012) 441e450 445Control Y, n ¼ 26 and elderly: Control E, n ¼ 14) controls by
a sandwich ELISA as described previously [14]. Results are indicated
as ng of sHSP60/mL. All assays were carried out in triplicates.
3.5.2. Anti-hHSP60 autoantibodies
The levels of anti-hHSP60 autoantibodies present in plasma/
serum from donors with 7 EL and 8 LL and healthy (young: Control
Y, n ¼ 26 and elderly: Control E, n ¼ 14) controls were determined
by ELISA as described [21]. Results are indicated as anti-hHSP60
autoantibody titers. All assays were carried out in triplicates.3.6. Statistical analysis
Datawere expressed as the mean SEM. Statistical analysis was
performed using the Student’s two-tailed t test. Differences were
considered signiﬁcant at p < 0.05.4. Results
4.1. T-cells are present in early atherosclerotic lesions
HSP60 was expressed by ECs at arterial branching sites stressed
by turbulent blood ﬂow conditions [22] (Fig. 1A); simultaneous
expression of adhesion molecules, such as VCAM-1 (CD106)
(Fig. 1B, C) and E-selectin (Fig. 1D) was detected at very early stages
of the disease. HSP60 expression was also observed in intralesional
cells co-expressing CD40þ (Fig. 1E), an inﬂammatory marker and
co-stimulatory molecule, which plays an important role inFig. 2. Intralesional atherosclerotic T-cells are mostly memory effector T-cells. Surface
expression of CD4, CD8, CD45RO, CD45RA, CD25, and CD28 were determined in intra-
lesional CD3þ T-cells isolated from (A) EL (n ¼ 7) and (B) LL (n ¼ 8). CD4þ signiﬁcantly
predominate over CD8þ T-cells in atherosclerotic lesions (EL p < 0.005; LL p < 0.05).
Signiﬁcant differences in the surface expression of phenotypic markers are indicated in
EL and LL T-cells (*p < 0.05; **p < 0.01; ***p < 0.005). Phenotypic characterization was
performed by four-color ﬂowcytometry. Bars indicate the percentage of positive cells as
mean  SEM. These experiments were performed once (in triplicates) for each donor.atherosclerosis [23,24]. HSP60 was also demonstrated in HLA-DRþ
intralesional cells (Fig. 1F). Surface expression of adhesion mole-
cules provides the prerequisites for adhesion and subsequent
transmigration of circulating T-cells (CD3þ) (Fig. 1G), macrophages
(CD68þ) (Fig. 1H), mast cells (Fig. 1I), and dendritic cells (CD1aþ)
(Fig. 1J) into the intima. Both, CD4þ (Fig. 1K) and CD8þ (Fig. 1L) T-
cells were identiﬁed demonstrating that a speciﬁc immunologic-
inﬂammatory process was taking place intima. In LL (plaques),
CD3þ (Fig. 1M), CD4þ (Fig. 1N), CD8þ (Fig. 1O), and CD68þ (Fig. 1P)
cells were present. CD3þ T-cells (CD4þ > CD8þ) prevailed over
CD68þ macrophages in EL, the opposite was true in LL.4.2. T-cells from early lesions are mostly CD4 memory effector T-
cells
T-cells isolated from EL were mostly CD4þ T-cells with high
expression of the memory cell marker CD45RO and almost
complete down-regulation of CD45RA (Fig. 2A). A subset of these
cells co-expressed CD25 and showed a modest accumulation of
cells lacking the expression of the co-stimulatory molecule CD28.
Thus, the dominant phenotype of T-cells from EL is the
CD4þCD45ROþCD25þCD28 effector memory type (Fig. 2A).
Although T-cells isolated from LL also showed an effector memory
phenotype (Fig. 2B), therewas an increase in the number of CD8þ T-
cells at this stage of the disease.Fig. 3. T-cells isolated from atherosclerotic lesions produce the proinﬂammatory
cytokine IFNg. IFNg, IL-4, IL-10, IL-17, and TGFb production in CD4þ and CD8þ T-cells
were determined in (A) EL (n ¼ 7) and (B) LL (n ¼ 8) donors by intracellular cytokine
analysis after unspeciﬁc stimulation with PMA ionomycin. IFNg-, IL-4-(**p < 0.01), and
IL-17-producing CD4þ T-cells were predominantly present as compared with the
cytokine proﬁle of CD8þ T-cells in EL (*p < 0.05). No signiﬁcant differences were
observed in the cytokine production proﬁle within LL T-cells. However, a signiﬁcant
increase in the frequency of IFNg-producing CD8 was observed in LL T-cells as
compared with EL T-cells (*p < 0.05). Bars indicate the percentage (mean  SEM) of
positive cytokine-producing cells by four-color cytometry. These experiments were
performed once for each donor.
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IFNg
Both CD4þ andCD8þ T-cells producedhigher levels of IFNg than IL-
10, IL-17, and TGFb (Fig. 3). Interestingly, in EL, CD4þ T-cells signiﬁ-
cantly contributed to the increased levels of IFNg, IL-4 (p < 0.01), and
IL-17 as compared to CD8þ T-cells (p < 0.05) whereas, there was
a signiﬁcant increase (p < 0.05) in the percentage of IFNg-producing
CD8þ T-cells isolated from LL (Fig. 3B) [13]. Furthermore, a Th1-driven
cytokine production by LL-derived cells is conﬁrmed by the reduction
of IL-4-producing CD4þ T-cells at late stages of the disease (Fig. 3B).
4.4. Autoreactive T-cells recognizing hHSP60 are present in early
atherosclerotic lesions
Autoreactive T-cells with high proliferative capacity against the
whole hHSP60 protein (S.I. ¼ 3.3  0.6) were identiﬁed in EL.
Stimulation with speciﬁc regions of the protein represented in the
different peptide pools resulted in proliferation of these T-cells
(Fig. 4, Supplementary Figure 3). Peptide pools III (positive/total
donors: 2/7), V (2/7), VI (3/7), VII (3/7), VIII (2/7), IX (4/7), X (2/7), and
XII (5/7) (Fig. 4, Table 2) induced proliferative responses by T-cells
from EL from multiple donors suggesting the presence of athero-
genic HSP60 peptides involved in the initiation of the disease.
4.5. Autoreactive T-cells from advanced atherosclerotic lesions
display restricted peptide recognition
T-cells from LL also showed proliferation in response to stimu-
lation with whole rhHSP60 (S.I. ¼ 2.3  0.1) (Fig. 5, Supplementary0
5
10
α
CD
3/
α
CD
28
PH
A
Co
nt
ro
l
w
ho
le
 h
H
SP
60
I II III IV
S
.
I
.
12
22
32
Fig. 4. EL T-cells proliferate in response to whole hHSP60 protein and recognize hHSP60-d
isolated from 7 EL donors was evaluated upon stimulation with either whole hHSP60 or hHS
anti-CD3/anti-CD28 antibodies (aCD3/aCD28) were used for positive controls. Antigen w
(S.I.  SEM). All assays were carried out in triplicates.Figure 4) which, interestingly, is restricted to a particular region of
the protein (amino acids 401e510) represented by pools IX and X
(Fig. 5, Supplementary Figure 4). These ﬁndings are in agreement
with earlier results [13] demonstrating that T-cells from LL display
a highly monoclonal and oligoclonal TCRa/b repertoire.4.6. Fine speciﬁcityofautoreactive intralesional atherosclerotic T-cells
Autoreactive intralesional atherosclerotic T-cells with a positive
proliferative response to hHSP60 peptide pools were then screened
against each of the individual overlapping peptides forming the
respective pool (Supplementary Table 2). T-cells fromEL recognized
a total of 24 hHSP60 peptides (Supplementary Figure 4,
Supplementary Table 3) eight of which induced proliferation of T-
cells (Table 3), suggesting that these peptides may be involved in
the initiation of the disease. Peptide 111 (551e565) was recognized
by 71.4% of T-cells from EL while peptide 54 (266e280), 57
(281e295), 66 (326e340), and 84 (416e430) were recognized by
42.9% of T-cells. Peptides 50 (246e260), 85 (421e435), and 88
(436e450) were recognized by 28.6% of T-cells from EL (Table 3). In
contrast, of the 19 peptides recognized by T-cells from LL, peptides
85 (421e435) and 95 (471e485) induced proliferative response in
75% of T-cells, while overlapping peptides 84 (416e430) and 96
(476e490) were recognized by 50% of T-cells (Table 3,
Supplementary Figure 5, Supplementary Table 4). Interestingly,
both EL and LL T-cells recognized peptides 84 and 85. No reactivity
was observed against a non-related control peptide (pepC). Taken
together, these results demonstrate a highly speciﬁc reactivity of T-
cells from EL to hHSP60 peptides. Additionally, the cellular immune
response to the HSP60 epitopes in LL was increasingly restricted.V VI VI
I
VI
II IX X XI XI
I
EL1
EL2
EL3
EL4
EL5
EL6
EL7
erived peptide pools. The proliferative cellular response of 1  104 intralesional T-cells
P60 peptide pools (indicated by Roman numerals, all at 10 mg/mL). PHA and monoclonal
as omitted in the negative control (Control). Data are shown as stimulation index
Table 2
Reactivity of T-cells from early atherosclerotic lesions to rhHSP60 protein and hHSP60-derived peptide pools IeXII.
Donor S.I.
hHSP60 I II III IV V VI VII VIII IX X XI XII
EL1 7.1 2.0 2.0 3.0 1.7 1.6 3.3 2.0 1.1 3.5 1.4 1.8 3.4
EL2 2.5 0.6 0.5 0.7 1.5 1.0 0.6 0.9 1.1 1.2 2.8 1.6 3.0
EL3 3.0 1.5 1.8 1.6 2.0 9.6 4.1 4.3 5.1 2.8 1.0 1.0 1.0
EL4 2.9 1.6 5.4 2.2 1.9 1.3 3.0 2.5 4.8 4.0 2.0 1.9 5.7
EL5 2.0 1.6 1.3 1.3 2.8 3.2 1.3 1.6 1.6 2.8 3.0 1.6 2.4
EL6 2.4 2.0 1.7 1.5 1.7 1.6 0.7 0.8 1.2 0.8 0.8 3.0 2.7
EL7 3.5 1.8 1.2 1.5 1.4 0.7 1.0 3.3 1.5 1.6 1.3 1.1 1.9
T-cell immune response to whole hHSP60 and twelve peptide pools (Roman numerals) is shown for 7 patients with EL. The response was considered positive when S.I. was
higher than two and this is shown in bold.
G. Almanzar et al. / Journal of Autoimmunity 39 (2012) 441e450 4474.7. sHSP60 and anti-HSP60 autoantibody production may be an
indicator of atherosclerosis stage
Levels of circulating sHSP60 present in plasma of LL donors
(310 57.8) was almost double of that found in plasma of EL donors
or in the control groups (Fig. 6A), (EL: 78.6  25.2; Control Y:
167  24; Control E: 131  35.7). However, no signiﬁcant differ-
ences were found between EL and the healthy control groups.
The levels of anti-HSP60 autoantibodies (expressed as titer) in
the four study groups were determined. Again, signiﬁcantly higher
titers of autoantibodies were detected in LL (1070  213.6) as
compared to the EL (134.5  28.2) donors and the control groups
(Control Y: 364.8  73; Control E: 416  112.8) (Fig. 6B). These
results conﬁrm earlier ﬁndings from our group that patients with LL
display increased amounts of circulating sHSP60 and anti-HSP60
autoantibodies [14,21]. However, no difference in these humoral
atherosclerosis biomarkers emerged in persons with EL compared
to healthy controls.
5. Discussion
HSP60 have been shown to play an important role in the
generation and progression of atherogenesis. Speciﬁc T-cells andFig. 5. LL T-cells display restricted peptide recognition. S.I. of 1 104 T-cells isolated from 8 L
(indicated by Roman numerals, all at 10 mg/mL). PHA and monoclonal anti-CD3/anti-CD28
negative control (Control). Data are shown as stimulation index (S.I.  SEM). All assays weantibodies generated against HSP60 following recurrent microbial
infections carry the danger of a cross-reaction between pro and
eukaryotic (microbial and human) HSP60. Biochemically altered
autologous HSP60 can also lead to the formation of bona ﬁde
autoreactive HSP60-speciﬁc T-cells and autoantibodies [18,25]. In
humans, peripheral HSP60-reactive T-cells from young clinically
healthy persons correlate with increased intima-media thickness
(IMT) at different vascular territories [26,27]. However, anti-
hHSP60 reactivity of peripheral T-cells from elderly persons did
not correlate with an increased IMT, suggesting that HSP60-speciﬁc
cellular immunity plays an important role at very early stages of the
disease, while anti-hHSP60 antibodies seem to have an accelerating
and perpetuating effect [28]. Furthermore, T-cells isolated from LL
show reactivity to bacterial and human HSP60, have a restricted T-
cell repertoire, and recognize HSP60-derived peptides [12,13,29].
Despite the obviously important role of HSP60 in the progres-
sion of atherosclerosis, the immune response of T-cells from human
EL, clinically still inapparent atherosclerotic lesions has not been
analyzed so far. In the present study, HSP60 expression on ECs from
EL and simultaneous up-regulation of adhesion molecules, such as
VCAM-1 and E-selectin (Fig. 1), previously shown in LL, were
observed [11]. This allows for interaction of HSP60-speciﬁc T-cells
with stressed ECs under arterial blood ﬂow conditions [30].L donors upon stimulation with either whole hHSP60 protein or hHSP60 peptide pools
antibodies (aCD3/aCD28) were used as positive control. Antigen was omitted in the
re carried out in triplicates.
Table 3
Atherogenic peptides recognized by T-cells from early atherosclerotic lesions (EL)
and from advanced late atherosclerotic lesions (LL).
Number Sequence Location Frequency
Atherogenic peptides from early atherosclerotic lesions
50 LSEKKISSIQSIVPA 246e260 2/7
54 AHRKPLVIIAEDVDG 266e280 3/7
57 EALSTLVLNRLKVGL 281e295 3/7
66 GEEGLTLNLEDVQPH 326e340 3/7
84 EKKDRVTDALNATRA 416e430 3/7
85 VTDALNATRAAVEEG 421e435 2/7
88 IVLGGGCALLRCIPA 436e450 2/7
111 KEEKDPGMGAMGGMG 551e565 5/7
Atherogenic peptides from late atherosclerotic lesions
84 EKKDRVTDALNATRA 416e430 4/8
85 VTDALNATRAAVEEG 421e435 6/8
95 TLKIPAMTIAKNAGV 471e485 6/8
96 AMTIAKNAGVEGSLI 476e490 4/8
Eight common HSP60 peptides induced a proliferative response in early athero-
sclerotic lesion (EL) and four in late atherosclerotic lesions (LL). Overlapping amino
acids are represented in bold.
G. Almanzar et al. / Journal of Autoimmunity 39 (2012) 441e450448Intralesional activated CD40þ/HLA-DRþ mononuclear cells also
displayed HSP60 expression, suggesting that HSP60 may be
implicated in the activation and maturation of DCs as observed in
Hodgkin’s disease [31]. In fact, HSP60 may act as a “danger signal”
for pre-existing adaptive immunity. CD4þ and CD8þ T-cells as well
as macrophages and DCs are present within the intima providing
the appropriate microenvironment for an initial antigen-driven T-
cell-mediated inﬂammatory process. T-cells from EL are0
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Fig. 6. Soluble HSP60 (sHSP60) and anti-hHSP60 IgG autoantibody production may be
an indicator of the atherosclerosis stage. Levels of circulating (A) sHSP60 (ng/mL) and
(B) anti-hHSP60 IgG autoantibodies (titer) were determined in the plasma of EL (n ¼ 7)
and LL (n ¼ 8) donors, young controls (control Y, n ¼ 26), and elderly controls (control
E, n ¼ 14) by ELISA. Values are indicated as mean  SEM. Signiﬁcant differences are
shown as follows: (A) sHSP60: EL vs LL (***p < 0.005); LL vs Control Y (p < 0.005); LL
vs control E (AAAp < 0.005), (B) Anti-hHSP60 IgG autoantibodies: EL vs LL
(***p < 0.005); LL vs Control Y (p< 0.005); LL vs control E (AAAp< 0.005). All assays
were carried out in triplicates.predominantly CD4þ with a memory effector phenotype charac-
terized by the expression of CD25. Here we demonstrate, albeit on
morphological evidence, that HSP60-speciﬁc CD4þCD25þCD45ROþ
T-cells interact with ECs that express HSP60 and adhesion mole-
cules on their surface after being exposed to various risk factors at
sites with predilection for later development of atherosclerotic
lesions. If such risk factors persist, the inﬂammatory process
progresses within the intimawhere it is continuously stimulated by
intralesional HSP60-expressing cells.
T-cells from early lesions produced high amounts of the pro-
inﬂammatory cytokine IFNg while the Th2 cytokine IL-4 was
detected only at low levels (Fig. 3). It has been demonstrated in
several studies that atherosclerosis can be attenuated via Th1
cytokine inhibition [32e34] and/or with stimulation of Th2 cyto-
kine production [35,36]. The accumulation of IFNg-producing CD8þ
T-cells in atherosclerotic plaques may contribute to a general
increase in the serum level of the IFNg, as reﬂected by high plasma
levels of neopterin in patients with complex carotid plaques [37],
acute coronary syndrome (ACS) [38e40], and chronic CMV infec-
tions [41].
This study provides functional proof for the presence of autor-
eactive hHSP60-speciﬁc T-cells in early stages of the disease.
Proliferation of T-cells from in response to hHSP60, and their
recognition of hHSP60-derived peptide pools (Fig. 4, Table 2)
corroborate the notion of a local antigen-driven process. It is of
interest to compare our observations on T-cell lines from both EL
and LL with those of Benagiano et al. on T-cell clones from LL only
[12]. Furthermore, while we assessed T-cell reactivity exclusively to
hHSP60-derived T-cell peptides, Benagiano et al. also investigated
cross-reactivity against Chlamydia pneumoniae HSP60 (cHSP60).
With respect to LL, we conﬁrmed the data of Benagiano et al. Since
all four epitopes of hHSP60 (Table 3) were also identiﬁed by these
authors, two speciﬁc for hHSP60 (471e485 and 476e490) and two
cross-reactive between hHSP60 and cHSP60 (416e430 and
421e435) [12]. More importantly, EL, not yet been studied by other
authors so far, contain T-cells that show interesting parallels to the
ﬁndings of Benagiano et al. as well to our own data on LL T-cells.
Seven of the eight EL-associated hHSP60 epitopes described by us
(Table 3) were also identiﬁed by these authors studying LL T-cells
for reactivity to either hHSP60 and/or cHSP60 [12]. In the present
study, two of the eight EL hHSP60 epitopes were also recognized by
LL T-cells (416e430 and 421e435). One EL HSP60 epitope
(551e565) recognized by T-cells derived from more than 70% of EL
appeared neither in the investigation of LL by Benagiano et al. nor
in our present study [12]. Except for the latter epitope, this
congruence is a strong indication that these hHSP60 epitopes
recognized already by EL T-cells play a pathogenic role throughout
atherogenesis and may represent interesting early targets for
prevention and therapy. However, taking into account the fact that
such an elaborate investigation so far could, of course, only be
performed in a limited number of subjects with inapparent lesions,
the issue of private vs common, i.e. shared potentially atherogenic,
hHSP60 epitopes has to be considered in the context of personal-
ized medicine.
Stressed cells up-regulate mitochondrial production of HSP60
that are then translocated into the cytosol, transported to the cell
surface, and released into the microenvironment by mechanisms
that are still not well understood [42,43]. LL donors had signiﬁ-
cantly higher serum levels of sHSP60 than donors with EL or
healthy controls (Fig. 6). However, no difference in serum levels of
sHSP60 was found between EL donors and healthy controls. These
ﬁndings corroborate our previous notion that levels of circulating
sHSP60 may be an indicator of cardiovascular diseases in general
and advanced degree of atherosclerosis in particular [14,44]. In fact,
increased levels of circulating sHSP60may reﬂect the inﬂammatory
G. Almanzar et al. / Journal of Autoimmunity 39 (2012) 441e450 449processes occurring in the arterial wall as well as the release from
necrotic cells within the plaque [45]. Extracellular HSP60 can
interact with endothelial surface receptors such as CD14, CD40 and
Toll-like receptors (TLRs), and activate antigen-presenting cells
[46,47].
Finally, we determined the levels of anti-hHSP60 autoantibodies
in the plasma of individuals with early and late lesions, as well as
two age- and sex-matched healthy control groups. The results
revealed a signiﬁcant increase in the levels of anti-hHSP60 auto-
antibodies in patients with LL in comparison to donors with EL and
healthy controls (Fig. 6). Interestingly, the group with early lesions
did not show a signiﬁcant difference in the anti-hHSP60 autoanti-
body titers compared with age-matched controls. Taken together,
both low levels of sHSP60 and low titers of anti-hHSP60 autoanti-
bodies in EL donors suggest that the humoral immune response is
not involved in the initiation of the disease, but rather in its
progression to advanced stages. This is comparable to what have
earlier been described in a large population-based prospective
study involving an elderly cohort, which showed a good correlation
between serum antibodies to mHSP65 and atherosclerosis [21],
while only a weak or no such correlation emerged in two younger
groups [26,27]. Furthermore, high levels of antibodies against
mHSP65 that cross-react with the hHSP60 are not only a predictor
of morbidity but also of mortality from cardiovascular disease [44].
These parameters have been shown by us and other laboratories to
be biomarkers for atherosclerosis independent of other classical
disease biomarkers [48]. If anti-HSP60 antibodies are injected into
mice directly they do of course act as endothelial stressors entailing
intimal arterial inﬁltrationmediated by HSP60-reactive T-cells [49].
In conclusion, this is the ﬁrst report determining the reactivity
of T-cells isolated from human early clinically still inapparent
atherosclerotic lesions reacting to potentially atherogenic peptides
from hHSP60. Furthermore, these T-cells produced abundant levels
of the pro-inﬂammatory cytokine IFNg and induced activation and
differentiation of macrophages, contributing to the thickening of
the intima at the known arterial predisposed sites. T-cells initiate
the inﬂammatory processes in the intima, and anti-hHSP60 auto-
antibodies accelerate and perpetuate the disease. The existence of
atherogenic “private” and “common”, i.e. shared hHSP60 peptides
makes these epitopes attractive diagnostic and therapeutic targets.
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